Evidence map›Paper›PMID 40284457›Full record

ArticlePharmaceutics2025

Mechanistic Insights into Sphingomyelin Nanoemulsions as Drug Delivery Systems for Non-Small Cell Lung Cancer Therapy.

Emma Ramos Docampo, Jenifer García-Fernández, Inés Mármol, Irene Morín-Jiménez, Maria Iglesias Baleato, María de la Fuente Freire

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emma Ramos DocampoNano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (CHUS), SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0009-0008-3905-570X
Jenifer García-FernándezNano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (CHUS), SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0002-2878-8886
Inés MármolInstitute for Health Research Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-3136-2480
Irene Morín-JiménezDIVERSA Technologies SL, 15782 Santiago de Compostela, Spain.
Maria Iglesias BaleatoNano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (CHUS), SERGAS, 15706 Santiago de Compostela, Spain.
María de la Fuente FreireNano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (CHUS), SERGAS, 15706 Santiago de Compostela, Spain.ORCID 0000-0003-0322-1469

Funding

Asociación Española Contra el Cáncer Ayudas Predoctorales AECC 2023 A CoruñaInstituto de Salud Carlos III, ISCIII PI21/01262Ministry of Economy and Competitiveness, Spain), co-financed by the European De-velopment Regional Fund ''A way to achieve Europe'' RTC2019-07227-1Xunta de Galicia by Grupos de Potencial Crecemento, Axencia Galega de Innovación (GAIN), Consellería de Economía, Emprego e Industria GPC IN607B2024/14
6 · The paper itself

Abstract

Sphingomyelin nanoemulsions (SNs) are promising drug delivery systems with potential for treating challenging tumors, including non-small cell lung cancer (NSCLC), which has a poor prognosis and a 5-year survival rate below 5%. Understanding the toxicity mechanisms and intracellular behavior of SNs is crucial for optimizing their therapeutic application. This study aims to investigate the interaction between SNs and A549 lung adenocarcinoma cells, focusing on their cytotoxic effects and mechanisms of cellular toxicity. SNs were synthesized and characterized for size, surface charge, and stability. A549 cells were treated with varying concentrations of SNs, and cellular uptake pathways were assessed using inhibitors of energy-dependent processes. Cytotoxicity was evaluated through an alamarBlue assay to determine the IC

Indexed as

drug deliverylysosomal escapemitochondrial targetingnon-small cell lung cancer (NSCLC)sphingomyelin nanosystemstargeted cancer therapy

Identifiers

PMID40284457
PMCPMC12030345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.